Litigation & Arbitration,
Health Care & Hospital Law
Sep. 25, 2023
Gilead, Teva to settle generics case for $247M
The direct purchaser class's expert estimated damages to them at $2.08 billion, so the settlement will constitute an 11.9% recovery. Senior U.S. District Judge Edward M. Chen said he would grant approval and issue an order shortly.
A federal judge in San Francisco is ready to preliminarily approve a $247 million settlement to resolve claims that Gilead Sciences Inc. struck a deal with generic medication manufacturer Teva Pharmaceutical Industries Ltd. to delay competing HIV generics from entering the market.
This agreement, if granted final approval, will release the claims of the direct purchasers who said they purchased Gilead’s HIV medication or their generic vers...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In